0000000000224975

AUTHOR

Martin N. Rossor

0000-0001-8215-3120

showing 6 related works from this author

Monitoring cognitive changes: Psychometric properties of six cognitive tests

2004

Objectives. Repeated neuropsychological assessments are often used to monitor change in cognitive functioning over time. Thus, knowledge about the reliability and stability of neuropsychological tests and the effects of age and IQ is of paramount importance. In this study we document, for six cognitive tests: test-retest reliabilities, practice effects, reliable change (RC) indices corrected for practice, and the impact of premorbid IQ and age. Design. A sample of 188 normal adults (aged 40-70 years) were administered, on two occasions, one or more of the following tests: the Graded Naming Test (GNT), the Silhouettes Test, two tests of verbal fluency, the Modified Wisconsin Card Sorting Tes…

AdultMalemedicine.medical_specialtyPsychometricsBRAIN-INJURYTest validityNeuropsychological TestsAudiologyNAMING TESTNational Adult Reading TestSeverity of Illness IndexMEMORY TESTDevelopmental psychologyDEMOGRAPHIC-VARIABLESTEST-PERFORMANCEmedicineHumansLONGITUDINAL PROFILESAchievement testVerbal fluency testAgedCARD SORTING TESTSettore M-PSI/02 - Psicobiologia E Psicologia FisiologicaIntelligence quotientmedicine.diagnostic_testReproducibility of ResultsGeneral MedicineNeuropsychological testMiddle AgedCognitive testTest (assessment)ALZHEIMERS-DISEASEVERBAL FLUENCYClinical PsychologyPractice PsychologicalFemaleTEST-RETEST RELIABILITYCognition DisordersPsychologyGraded Naming Test Silhouettes Test Verbal fluency tests Modified Wisconsin Card Sorting Test New Symbol Digit Test National Adult Reading Test (NART)
researchProduct

A second family with familial AD and the V717L APP mutation has a later age at onset

2006

Four mutations have been reported at the 717 codon of the amyloid precursor protein (APP), with valine substituted by isoleucine, glycine, phenylalanine, and leucine. While several families with the isoleucine substitution have been described, the other substitutions have been reported in only one family each worldwide. A family with the V717L APP mutation has been previously reported,1 with a mean age at onset of 38 years (range 35 to 39), based on four affected family members, and a mean age at death of 46 years (range 40 to 50). We have identified a second family with a later mean age at onset of 50 years (range 48 to 57) and mean age at death of 61 years (range 57 to 68). Family 171 is …

MalePediatricsmedicine.medical_specialtyMutation Missensemedicine.disease_causeAmyloid beta-Protein PrecursorAlzheimer DiseaseValineInternal medicinemedicineAmyloid precursor proteinHumansAge of OnsetAgedAge of Onset Aged Alzheimer Disease/genetics Alzheimer Disease/physiopathology Amino Acid Substitution Amyloid beta-Protein Precursor/genetics Female Humans Malle Middle Aged Mutation Missense PedigreeMutationSettore M-PSI/02 - Psicobiologia E Psicologia FisiologicabiologyMean ageMiddle AgedPedigreeEndocrinologyAmino Acid Substitutionbiology.proteinFemaleNeurology (clinical)IsoleucineNeurology
researchProduct

Mapping the onset and progression of atrophy in familial frontotemporal lobar degeneration

2005

Background: Frontotemporal lobar degeneration (FTLD) may be inherited as an autosomal dominant disease. Studying patients "at risk" for developing FTLD can provide insights into the earliest onset and evolution of the disease. Method: We carried out approximately annual clinical, MRI, and neuropsychological assessments on an asymptomatic 51 year old "at risk" family member from a family with FTLD associated with ubiquitin-positive and tau-negative inclusion bodies. We used non-linear (fluid) registration of serial MRI to determine areas undergoing significant regional atrophy at different stages of the disease. Results: Over the first 26 months of the study, the patient remained asymptomati…

PaperMalePathologymedicine.medical_specialtyDiseaseNeuropsychological TestsAsymptomaticBrain mappingAtrophy Brain/pathology Brain Mapping Dementia/pathology Disease Progression Female Follow-Up Studies Humans Male Middle Aged Neuropsychological TestsAtrophymental disordersmedicineHumansDementiaBrain MappingSettore M-PSI/02 - Psicobiologia E Psicologia FisiologicaNeuropsychologyfood and beveragesnutritional and metabolic diseasesBrainAutosomal dominant traitFrontotemporal lobar degenerationMiddle Agedmedicine.diseasenervous system diseasesPsychiatry and Mental healthDisease ProgressionDementiaFemaleSurgeryNeurology (clinical)Atrophymedicine.symptomPsychologyFollow-Up Studies
researchProduct

MRS SHOWS ABNORMALITIES BEFORE SYMPTOMS IN FAMILIAL ALZHEIMER DISEASE

2006

Background: Pathologic change in Alzheimer disease (AD) begins some years before symptoms. MRS has the potential to detect metabolic abnormalities reflecting this early pathologic change. Presenilin 1 (PS1) and amyloid precursor protein (APP) mutation carriers have a nearly 100% risk of developing AD and may be studied prior to symptom onset. Methods: Short echo time proton MR spectra were acquired from a midline posterior cingulate voxel in presymptomatic carriers of PS1 or APP mutations (“presymptomatic mutation carriers” [PMCs]; n = 7) and age- and sex-matched control subjects (n = 6). Ratios of N-acetyl aspartate (NAA), myo-inositol (MI), and choline-containing compounds (Cho) to creati…

AdultMalemedicine.medical_specialtyPathologyMagnetic Resonance SpectroscopyAlzheimer disease brain metabolism nuclear magnetic resonance spectroscopyAdolescentNeuropsychological TestsCreatineGastroenterologyPresenilinCentral nervous system diseasechemistry.chemical_compoundDegenerative diseaseAlzheimer DiseaseReference ValuesInternal medicinemental disordersmedicineHumansFamilySymptom onsetAge of OnsetChildSettore M-PSI/02 - Psicobiologia E Psicologia FisiologicaBrainInfantMiddle Agedmedicine.diseaseControl subjectsnervous system diseasesnervous systemchemistryChild PreschoolCarrier StateFemaleNeurology (clinical)Alzheimer's diseaseGeometric meanPsychology
researchProduct

The neuropsychology of variant CJD: a comparative study with inherited and sporadic forms of prion disease.

2005

Objective: To assess cognitive function in variant Creutzfeldt-Jakob disease (vCJD). We describe the neuropsychological profiles of 10 cases and compare these data with cross sectional data obtained from patients with histologically confirmed sporadic CJD and cases with inherited prion disease with confirmed mutations in the prion protein gene. Methods: Patients referred to the Specialist Cognitive Disorders Clinic at the National Hospital for Neurology and Neurosurgery and the National Prion Clinic at St Mary's Hospital, London for further investigation of suspected CJD were recruited into the study. The neuropsychological test battery evaluated general intelligence, visual and verbal memo…

AdultMalePaperPediatricsmedicine.medical_specialtyPrionsanimal diseasesDNA Mutational AnalysisNeuropsychological TestsCreutzfeldt-Jakob SyndromePrion DiseasesNational Prion Clinicmental disordersmedicineDementiaHumansCognitive declinePsychiatrymedicine.diagnostic_testSettore M-PSI/02 - Psicobiologia E Psicologia Fisiologicabusiness.industryNeuropsychologyNeuropsychological testCreutzfeldt-Jakob SyndromeMiddle Agedmedicine.diseasenervous system diseasesPsychiatry and Mental healthCross-Sectional StudiesAdult Cognition Disorders/etiology Creutzfeldt-Jakob Syndrome/complications Creutzfeldt-Jakob Syndrome/genetics Creutzfeldt-Jakob Syndrome/psychology Cross-Sectional Studies DNA Mutational Analysis Disease Progression Female Humans Male Middle Aged Neuropsychological Tests Prion Diseases/genetics Prion Diseases/psychology Prions/genetics Visual PerceptionDisease ProgressionVisual PerceptionSurgeryFemaleNeurology (clinical)Verbal memorybusinessCognition DisordersExecutive dysfunctionJournal of neurology, neurosurgery, and psychiatry
researchProduct

Pure Progressive Amnesia and the APPV717G Mutation

2009

We report an isolated, slowly progressive, pure amnestic phenotype in a 59-year-old member of a family affected by autosomal dominant familial Alzheimer disease. Early-onset Alzheimer disease in this family was associated with a V717G mutation in the amyloid precursor protein gene (APP). Subjective impairment of episodic memory began in our subject at the age of 44 years and subsequent, longitudinal neuropsychologic assessment confirmed progressive, severe, global impairment of memory functions over a period of 14 years with preservation of other cognitive domains. The mean annual hippocampal atrophy rate, determined by volumetric magnetic resonance imaging was intermediate between values p…

AdultMaleAgingPathologymedicine.medical_specialtyGlycineAmnesiaHippocampusAmyloid beta-Protein PrecursorAtrophyAlzheimer DiseasemedicineHumansDementiaMemory disorderEpisodic memoryAgedSettore M-PSI/02 - Psicobiologia E Psicologia FisiologicaCognitive disorderValineMiddle Agedmedicine.diseaseAPPV717G mutation.PedigreePsychiatry and Mental healthClinical PsychologyPhenotypeMutationDisease ProgressionPure progressive amnesiaFemaleAmnesiaAtrophyGeriatrics and Gerontologymedicine.symptomAlzheimer's diseasePsychologyGerontologyFrontotemporal dementia
researchProduct